Clinical Trial Finder Search Results

About the Fight CRC Clinical Trial Finder

This Trial Finder is a one-stop place to find and learn more about high-impact clinical trials for colorectal cancer patients with advanced colon or rectal cancer. Originally created by the late Dr. Tom Marsilje as a curated spreadsheet of trials, the FightCRC’s Trial Finder is a resource to find research studies that are open in your geography, and for which you may be eligible. The current data is now for metastatic, stage IV patients with both MSS and MSI-H status. The list of trials here is sourced from the ClinicalTrials.gov website and curated with Comments and Helpful Links. The searches can be focused on immunotherapy-centered trials and narrowed to studies enrolling patients who already have received immunotherapies.

Medical Disclaimer

The information contained in this website is not intended to recommend the self management of health problems, medical conditions or wellness. It is not intended to endorse or recommend any particular type of medical treatment, physician or treatment facility. Should any reader have any health care related questions, promptly call or consult your physician or healthcare provider. The information contained in this website should NOT be used by any reader to disregard medical and/or health related advice or provide a basis to delay consultation with a physician or a qualified healthcare provider. Fight Colorectal Cancer disclaims any liability based on information provided in this website.

Location

MS status

Recruitment Status

Phase

Drugs

Prior Immunotherapy Allowed

NCT ID

Title key word search

Date Trial Added

From To

View:

Compact Expanded

PDF Excel CSV

NCT ID	Title	Phase	Date Added	Location	Prior IO Allowed	CRC-directed	Status	Drugs	Tags
NCT ID NCT04776148	TitleStudy of Lenvatinib (MK-7902/E7080) in Combination With Pembrolizumab (MK-3475) Versus Standard of Care in Participants With Metastatic Colorectal Cancer (MK-7902-017/E7080-G000-325/LEAP-017)	Phase Phase 3	Date Added 2021-03-01	Location California, United States Georgia, United States Illinois, United States Maryland, United States Michigan, United States Montana, United States Oregon, United States Pennsylvania, United States Virginia, United States Washington, United States Argentina Australia Canada China Denmark Germany Israel Japan Korea, Republic of Russian Federation Spain Taiwan Turkey United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Lenvatinib, Pembrolizumab, Regorafenib, TAS-102 (trifluridine and tipiracil)	Tags MSS/ MMRp
NCT ID NCT03947385	TitleStudy of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	Phase Phase 1, Phase 2	Date Added 2019-05-13	Location California, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia Canada	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Binimetinib, Crizotinib, IDE196	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT05838768	TitleStudy of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.	Phase Phase 1	Date Added 2023-05-03	Location California, United States Massachusetts, United States New York, United States Texas, United States Belgium China France Germany Israel Italy Japan Korea, Republic of Norway Singapore Spain Sweden Taiwan United Kingdom	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs HRO761, Irinotecan	Tags MSI-H/ MMRd
NCT ID NCT04092673	TitleStudy of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies	Phase Phase 1	Date Added 2019-09-17	Location California, United States Michigan, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Texas, United States Virginia, United States	Prior IO Allowed No	CRC-directed No	Status Recruiting	Drugs eFT226, eFT226	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03069469	TitleStudy of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor	Phase Phase 1, Phase 2	Date Added 2017-03-03	Location California, United States Colorado, United States Florida, United States Massachusetts, United States New York, United States Oregon, United States Tennessee, United States Australia Canada France Italy Netherlands Poland Spain United Kingdom	Prior IO Allowed Yes	CRC-directed No	Status Active, not recruiting	Drugs DCC-3014	Tags MSS/ MMRp
NCT ID NCT03545815	TitleStudy of CRISPR-Cas9 Mediated PD-1 and TCR Gene-knocked Out Mesothelin-directed CAR-T Cells in Patients With Mesothelin Positive Multiple Solid Tumors.	Phase Phase 1	Date Added 2018-06-04	Location China	Prior IO Allowed Yes	CRC-directed No	Status Recruiting	Drugs anti-mesothelin CAR-T cells	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03950154	TitleStudy of Chemotherapy Combination With Autologous Cell Immunotherapy in the Recurrent and Metastatic Colorectal Cancer	Phase Phase 3	Date Added 2019-05-15	Location China	Prior IO Allowed No	CRC-directed Yes	Status Recruiting	Drugs Bevacizumab Injection [Avastin], capecitabine, oxaliplatin, PD1-T cells	Tags MSI-H/ MMRd, MSS/ MMRp
NCT ID NCT03170960	TitleStudy of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors	Phase Phase 1	Date Added 2017-05-31	Location Arizona, United States California, United States Colorado, United States Connecticut, United States District of Columbia, United States Florida, United States Georgia, United States Illinois, United States Kansas, United States Kentucky, United States Louisiana, United States Massachusetts, United States Michigan, United States Minnesota, United States Missouri, United States Nebraska, United States Nevada, United States New Jersey, United States New York, United States Ohio, United States Oklahoma, United States Oregon, United States Pennsylvania, United States South Carolina, United States Texas, United States Utah, United States Virginia, United States Australia Belgium France Germany Italy Netherlands Spain United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs Atezolizumab, Cabozantinib	Tags MSS/ MMRp
NCT ID NCT04963283	TitleStudy of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer	Phase Phase 2	Date Added 2021-07-15	Location Colorado, United States	Prior IO Allowed No	CRC-directed Yes	Status Active, not recruiting	Drugs Cabozantinib, Nivolumab	Tags MSS/ MMRp
NCT ID NCT05198934	TitleSotorasib and Panitumumab Versus Investigator’s Choice for Participants With Kirsten Rat Sarcoma (KRAS) p.G12C Mutation (CodeBreak 300)	Phase Phase 3	Date Added 2022-01-20	Location Alabama, United States California, United States District of Columbia, United States Florida, United States Georgia, United States Michigan, United States New York, United States North Carolina, United States Ohio, United States Pennsylvania, United States Tennessee, United States Texas, United States Australia France Germany Greece Italy Japan Korea, Republic of Mexico Spain Taiwan United Kingdom	Prior IO Allowed Yes	CRC-directed Yes	Status Active, not recruiting	Drugs	Tags MSI-H/ MMRd, MSS/ MMRp

Showing 51 to 60 of 299 entries